DOP2024000081A - Inhibidores de moléculas pequeñas de la proteasa específica de ubiquitina 1 (usp1) y sus usos - Google Patents
Inhibidores de moléculas pequeñas de la proteasa específica de ubiquitina 1 (usp1) y sus usosInfo
- Publication number
- DOP2024000081A DOP2024000081A DO2024000081A DO2024000081A DOP2024000081A DO P2024000081 A DOP2024000081 A DO P2024000081A DO 2024000081 A DO2024000081 A DO 2024000081A DO 2024000081 A DO2024000081 A DO 2024000081A DO P2024000081 A DOP2024000081 A DO P2024000081A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- usp1
- ubiquitin
- specific protease
- small molecule
- molecule inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021130284 | 2021-11-12 | ||
| CN2022123821 | 2022-10-08 | ||
| PCT/CN2022/131290 WO2023083285A1 (en) | 2021-11-12 | 2022-11-11 | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2024000081A true DOP2024000081A (es) | 2024-11-29 |
Family
ID=86335132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2024000081A DOP2024000081A (es) | 2021-11-12 | 2024-05-10 | Inhibidores de moléculas pequeñas de la proteasa específica de ubiquitina 1 (usp1) y sus usos |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20250066348A1 (https=) |
| EP (1) | EP4430049A4 (https=) |
| JP (1) | JP2024543497A (https=) |
| KR (1) | KR20240117555A (https=) |
| CN (1) | CN119173515A (https=) |
| AU (1) | AU2022387669A1 (https=) |
| CA (1) | CA3235603A1 (https=) |
| CL (1) | CL2024001398A1 (https=) |
| CO (1) | CO2024006278A2 (https=) |
| CR (1) | CR20240190A (https=) |
| DO (1) | DOP2024000081A (https=) |
| GE (1) | GEAP202416531A (https=) |
| IL (1) | IL312640A (https=) |
| JO (1) | JOP20240095A1 (https=) |
| MX (1) | MX2024005756A (https=) |
| PE (1) | PE20241350A1 (https=) |
| WO (1) | WO2023083285A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20240191A (es) | 2021-11-12 | 2024-09-13 | Insilico Medicine Ip Ltd | Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos |
| US20250382289A1 (en) * | 2022-02-18 | 2025-12-18 | Xizang Haisco Pharmaceutical Co., Ltd. | Pyrazolopyridine derivative and application thereof in medicine |
| WO2024022266A1 (en) * | 2022-07-25 | 2024-02-01 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heteroaryl compounds as inhibitors of usp1 |
| CN119522224A (zh) * | 2022-08-09 | 2025-02-25 | 上海济煜医药科技有限公司 | 含氮杂环化合物作为泛素-特异性蛋白酶1抑制剂的制备方法、应用及其用途 |
| IL319492A (en) * | 2022-09-20 | 2025-05-01 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | A carbonyl-fused heterocyclic derivative that acts as a ubiquitin-specific protease |
| CN120603835A (zh) * | 2023-01-20 | 2025-09-05 | 杭州英创医药科技有限公司 | 作为usp1抑制剂的化合物 |
| CN121511238A (zh) * | 2023-07-05 | 2026-02-10 | 江苏亚虹医药科技股份有限公司 | 嘧啶类化合物、其制备方法及其医药用途 |
| WO2025010245A1 (en) | 2023-07-06 | 2025-01-09 | Exelixis, Inc. | Fused pyrazole derivatives as usp1 inhibitors |
| WO2025015905A1 (en) * | 2023-07-14 | 2025-01-23 | Laekna Therapeutics Shanghai Co., Ltd. | Pyrimidine compounds and their use as usp1 inhibitors |
| TW202530200A (zh) * | 2023-09-25 | 2025-08-01 | 大陸商上海濟煜醫藥科技有限公司 | 嗒𠯤酮類化合物作為泛素－特異性蛋白酶１抑制劑的製備方法、應用及其用途 |
| TW202530229A (zh) * | 2023-09-26 | 2025-08-01 | 大陸商上海濟煜醫藥科技有限公司 | 氮雜環胺類化合物作為泛素-特異性蛋白酶１抑制劑的製備方法、應用及其用途 |
| WO2025102016A1 (en) | 2023-11-10 | 2025-05-15 | Vrise Therapeutics, Inc. | Novel molecules as inhibitors of dna damage repair pathway |
| WO2025151705A1 (en) | 2024-01-10 | 2025-07-17 | Vrise Therapeutics, Inc. | Novel inhibitors of dna damage repair pathway |
| WO2025227060A1 (en) * | 2024-04-26 | 2025-10-30 | Insilico Medicine Ip Limited | Heterocyclic inhibitors of ubiquitin specific protease 1 (usp1) in combination with additional agents for use in the treatment of cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10189841B2 (en) * | 2015-11-20 | 2019-01-29 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
| BR112021010715A2 (pt) * | 2018-12-20 | 2021-11-16 | Ksq Therapeutics Inc | Pirazolopirimidinas substituídas e purinas substituídas e seu uso como inibidores de protease de processamento ubiquitina-específica 1 (usp1) |
| CA3168009A1 (en) * | 2020-02-14 | 2021-08-19 | KSQ Therapeutics, Inc. | Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors |
| KR20230098186A (ko) * | 2020-10-30 | 2023-07-03 | 케이에스큐 세러퓨틱스 인코포레이티드 | 치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도 |
| US20240182481A1 (en) * | 2021-02-15 | 2024-06-06 | Tango Therapeutics, Inc. | Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer |
| AU2022238886A1 (en) * | 2021-03-17 | 2023-09-14 | Medivir Ab | Purine derivatives as anticancer agents |
| WO2022199652A1 (en) * | 2021-03-24 | 2022-09-29 | Impact Therapeutics (Shanghai) , Inc | Five-membered heteroaryl-pyrimidine compounds as usp1 inhibitors and the use thereof |
| MX2023011709A (es) * | 2021-04-07 | 2023-10-12 | Forma Therapeutics Inc | Inhibidor de la proteasa 1 especifica de ubiquitina (usp1). |
-
2022
- 2022-11-11 GE GEAP202416531A patent/GEAP202416531A/en unknown
- 2022-11-11 CA CA3235603A patent/CA3235603A1/en active Pending
- 2022-11-11 IL IL312640A patent/IL312640A/en unknown
- 2022-11-11 MX MX2024005756A patent/MX2024005756A/es unknown
- 2022-11-11 AU AU2022387669A patent/AU2022387669A1/en active Pending
- 2022-11-11 JP JP2024528586A patent/JP2024543497A/ja active Pending
- 2022-11-11 EP EP22892078.1A patent/EP4430049A4/en active Pending
- 2022-11-11 US US18/708,686 patent/US20250066348A1/en active Pending
- 2022-11-11 CR CR20240190A patent/CR20240190A/es unknown
- 2022-11-11 KR KR1020247018880A patent/KR20240117555A/ko active Pending
- 2022-11-11 PE PE2024001034A patent/PE20241350A1/es unknown
- 2022-11-11 WO PCT/CN2022/131290 patent/WO2023083285A1/en not_active Ceased
- 2022-11-11 CN CN202280087722.8A patent/CN119173515A/zh active Pending
-
2024
- 2024-04-24 JO JOJO/P/2024/0095A patent/JOP20240095A1/ar unknown
- 2024-05-09 CL CL2024001398A patent/CL2024001398A1/es unknown
- 2024-05-10 DO DO2024000081A patent/DOP2024000081A/es unknown
- 2024-05-17 CO CONC2024/0006278A patent/CO2024006278A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4430049A1 (en) | 2024-09-18 |
| PE20241350A1 (es) | 2024-07-03 |
| AU2022387669A1 (en) | 2024-05-16 |
| CL2024001398A1 (es) | 2024-11-08 |
| IL312640A (en) | 2024-07-01 |
| CR20240190A (es) | 2024-09-13 |
| CN119173515A (zh) | 2024-12-20 |
| MX2024005756A (es) | 2024-09-06 |
| US20250066348A1 (en) | 2025-02-27 |
| JP2024543497A (ja) | 2024-11-21 |
| CO2024006278A2 (es) | 2024-05-30 |
| GEAP202416531A (en) | 2024-10-28 |
| EP4430049A4 (en) | 2025-12-17 |
| CA3235603A1 (en) | 2023-05-19 |
| KR20240117555A (ko) | 2024-08-01 |
| WO2023083285A1 (en) | 2023-05-19 |
| JOP20240095A1 (ar) | 2024-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2024000081A (es) | Inhibidores de moléculas pequeñas de la proteasa específica de ubiquitina 1 (usp1) y sus usos | |
| CL2024001411A1 (es) | Inhibidores de molécula pequeña de proteasa específica de ubiquitina 1 (usp1) y sus usos | |
| DOP2024000080A (es) | Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos | |
| ECSP20069418A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CL2022001671A1 (es) | Inhibidores de sos1 | |
| MX2021009246A (es) | Inmunomoduladores, composiciones y metodos de los mismos. | |
| CL2022003510A1 (es) | Inhibidores de cisteína proteasas y sus métodos de uso | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| CO2023005342A2 (es) | Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer | |
| DOP2024000231A (es) | Compuestos y usos de estos | |
| CL2021001656A1 (es) | Compuestos de imidazopiridina e imidazopiridina y sus usos. | |
| CL2023000371A1 (es) | Composiciones y métodos para inhibir la expresión de plp1. | |
| CO2023010940A2 (es) | Compuestos moduladores de gcn2 y usos de los mismos | |
| CO2024004970A2 (es) | Agentes degradantes de tyk2 y sus usos | |
| AR133953A1 (es) | Inhibidores del factor b del complemento y usos de los mismos | |
| DOP2024000225A (es) | Composiciones y métodos para inhibir la expresión de mapt | |
| MX2025001164A (es) | Inhibidores de calicreina plasmatica. | |
| CL2025000272A1 (es) | Derivados de arilo tricíclico y composiciones y métodos de los mismos | |
| AR131685A1 (es) | 1h-pirazol-4-carboxamidas sustituidas como inhibidores de sarm1 | |
| AR127843A1 (es) | Composiciones y métodos para modular la expresión de apoc3 | |
| CL2023001230A1 (es) | Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos | |
| MX2022001023A (es) | Compuestos de aminotiolester y usos de los mismos. | |
| MX2021009767A (es) | Moleculas de union de fmcr y usos de las mismas. | |
| AR129469A1 (es) | Inhibidores de rock y sus usos | |
| AR132459A1 (es) | Inhibidores de kras de pirrolidina |